ArticleScientific reports2017
Geographic variation in pneumococcal vaccine efficacy estimated from dynamic modeling of epidemiological data post-PCV7.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review.Human vaccines & immunotherapeutics · 2025Review
- Assessing the effect of social contact structure on the impact of pneumococcal conjugate vaccines.Scientific reports · 2025Article
- Inference of Pairwise Interactions from Strain Frequency Data Across Settings and Context-Dependent Mutual Invasibilities.Bulletin of mathematical biology · 2025Article
- A dynamic transmission model for assessing the impact of pneumococcal vaccination in the United States.PloS one · 2025Article
- Burden of Pertussis in Adults Aged 50 Years and Older: A Retrospective Database Study in England.Infectious diseases and therapy · 2023Article
- Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses.Nature immunology · 2022Review
- Vaccine manufacturing capacity in low- and middle-income countries.Bulletin of the World Health Organization · 2021Article
- The incremental burden of invasive pneumococcal disease associated with a decline in childhood vaccination using a dynamic transmission model in Japan: A secondary impact of COVID-19.Computers in biology and medicine · 2021Article
- Pneumococcal Meningitis and Its Sequelae - A Devastating CNS Disease.Journal of mother and child · 2020Article
- Epidemiological consequences of enduring strain-specific immunity requiring repeated episodes of infection.PLoS computational biology · 2020Article
- The Human Vaccines Project: Towards a comprehensive understanding of the human immune response to immunization.Human vaccines & immunotherapeutics · 2018Review
- Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination.Journal of the Royal Society, Interface · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although mean efficacy of multivalent pneumococcus vaccines has been intensively studied, variance in vaccine efficacy (VE) has been overlooked. Different net individual protection across settings can be driven by environmental conditions, local serotype and clonal composition, as well as by socio-demographic and genetic host factors. Understanding efficacy variation has implications for population-level effectiveness and other eco-evolutionary feedbacks. Here I show that realized VE can vary across epidemiological settings, by applying a multi-site-one-model approach to data post-vaccination. I analyse serotype prevalence dynamics following PCV7, in asymptomatic carriage in children attending day care in Portugal, Norway, France, Greece, Hungary and Hong-Kong. Model fitting to each dataset provides site-specific estimates for vaccine efficacy against acquisition, and pneumococcal transmission parameters. According to this model, variable serotype replacement across sites can be explained through variable PCV7 efficacy, ranging from 40% in Norway to 10% in Hong-Kong. While the details of how this effect is achieved remain to be determined, here I report three factors negatively associated with the VE readout, including initial prevalence of serotype 19F, daily mean temperature, and the Gini index. The study warrants more attention on local modulators of vaccine performance and calls for predictive frameworks within and across populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.